Introduction: Hemorrhagic tendency in patients with myelodysplastic syndrome (MDS) is mainly attributed to thrombocytopenia. However, platelet function in these patients has not been thoroughly investigated. Aim: The aim of our study is to evaluate platelet function in patients with primary MDS. Methods: Platelet function was studied with aggregometry in response to ristocetin, collagen, ADP and adrenaline in 26 MDS patients and 15 healthy individuals. Results: Aggregation was defective in 21 patients (80.7%). Adrenaline was the agonist with the most profound defect (45.9%), followed by ADP (58.7%), whereas aggregation with ristocetin and collagen was at the borderline. Abnormal aggregation to all four agonists was detected in 6 patients (23%). On the contrary, aggregation results were normal in only 5 patients (19.2%). RAEB-t (refractory anemia with excess blasts in transformation) patients were most seriously affected. Conclusions: MDS patients have impaired platelet aggregation in response to one or more stimulants. Platelet aggregation was not statistically different between MDS patients at early stages of the disease (<12 months) and those at later stages (>12 months). Defective platelet aggregation is strongly related to MDS of worse prognosis. None of our patients was detected to have hyperfunctional platelets, defined as platelets aggregating spontaneously. Functional defects in MDS do not elicit hemorrhagic tendency.

Keywords:
Erythropoiesis, Myelodysplastic syndromes, Platelet aggregation
1.
Greenberg PL, Young NS, Gattermann N: Myelodysplastic syndromes. Hematology (Am Soc Hematol Educ Program) 2002;23:136–161.
2.
Mittelman M, Zeidman A: Platelet function in the myelodysplastic syndromes. Int J Hematol 2000:71:95–98.
3.
Gerrard JM, McNicol A: Platelet storage pool deficiency, leukemia, and myelodysplastic syndromes. Leuk Lymphoma 1992;8:277–281.
4.
Hofmann WK, Kalina U, Koschmieder S, Seipelt G, Hoeltzer D, Ottman O: Defective megakaryocytic development in myelodysplastic syndromes. Leuk Lymphoma 2000;38:13.
5.
Geissler D, Zwierzina H, Pechlaner C, Gaggl S, Schmalzl F, Konwalinka G, Braunsteiner H: Abnormal megakaryopoiesis in patients with myelodysplastic syndromes: analysis of cellular and humoral defects. Br J Haematol 1989;73:29–35.
6.
Mittelman M, Sokolover N, Zeidman A, Redlich O, Cohen A, Fradin Z: Platelet aggregation and its clinical significance in the myelodysplastic syndromes. Leuk Res 1999;23(suppl 1):s24.
7.
Oguma S, Yoshida Y, Uchino H, Maekawa T, Nomura T, Mizogushi H: Clinical characteristics of Japanese patients with primary myelodysplastic syndromes: a co-operative study based on 838 cases. Anemia Study Group of the Ministry of Health and Welfare. Leuk Res 1995;19:219–225.
8.
Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, Sanz M, Vallespi T, Hamblin T, Oscier D, Ohyashiki K, Toyama K, Aul C, Mufti G, Bennett J: International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997;89:2079–2088.
9.
Zeidman A, Horowits A, Kanter P, Stein G, Redlich O, Cohen A, Mittelman M: Platelet function and its clinical significance in the myeloproliferative disorders. Haema 2005;8:64–69.
10.
Trip MD, Cats VM, van Capelle FJ, Vreeken J: Platelet hyperreactivity and prognosis in survivors of myocardial infarction. N Engl J Med 1990;322:1549–1554.
11.
Caen J, Sultan Y, Dreyfus B: Study of platelet functions in 7 cases of refractory anemia. Nouv Rev Fr Hématol 1969;9:123–129.
12.
Pamphilon DH, Aparicio SR, Roberts BE, Menys VC, Tate G, Davies JA: The myelodysplastic syndromes – A study of haemostatic function and platelet ultrastructure. Scand J Haematol 1984;33:486–491.
13.
Meschengieser S, Blanco A, Maugeti N, Dupont J, Fernandez J, de Tezanos Pinto M, Lazzari M: Platelet function and intraplatelet von Willebrand factor antigen and fibrinogen in myelodysplastic syndromes. Thromb Res 1987;46:601–606.
14.
Zeidman A, Sokolover N, Fradin Z, Cohen A, Redlich O, Mittelman M: Platelet function and its clinical significance in the myelodysplastic syndromes. Hematol J 2004;5:234–238.
© 2007 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.